Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Shawn Mahmood"'
Autor:
Deanne Tibbitts, Alka Puri, Shannon K. McWeeney, Jeffrey W. Tyner, Sophia Jeng, Raffaella Pippa, A. Thomas Look, Megan M. Cleary, Nameeta P. Richard, Rosalie C. Sears, Anupriya Agarwal, Bill H. Chang, Michael P. Vitek, Shawn Mahmood, María D. Odero, Dale J. Christensen
Publikováno v:
Oncotarget
Recent evidence suggests that inhibition of protein phosphatase 2A (PP2A) tumor suppressor activity via the SET oncoprotein contributes to the pathogenesis of various cancers. Here we demonstrate that both SET and c-MYC expression are frequently elev
Autor:
Johannes Elferich, Mona M.Hosseini, Sherif Abdelhamed, Jason E. McDermott, Brian J. Druker, Ujwal Shinde, Karin D. Rodland, Anupriya Agarwal, Shawn Mahmood, Samuel H. Payne, Monika A. Davare, Tao Liu, Jack W. Singer, Motomi Mori, Andy Kaempf, Stephen E. Kurtz
Publikováno v:
Leukemia. 32(11)
Interleukin-1 receptor-associated kinase 1 (IRAK1), an essential mediator of innate immunity and inflammatory responses, is constitutively active in multiple cancers. We evaluated the role of IRAK1 in acute myeloid leukemia (AML) and assessed the inh
Autor:
Monika A. Davare, Johannes Elferich, Jack W. Singer, Ujwal Shinde, Bernadette Maertens, Stephen E. Kurtz, Shawn Mahmood, Brian J. Druker, Christopher O. Eden, Alka Puri, Cristina E. Tognon, Anupriya Agarwal
Publikováno v:
Blood. 128:3514-3514
Background: The bone marrow microenvironment modulates response of acute myeloid leukemia (AML) to therapy. Thus necessitating the identification of microenvironment-driven signaling mechanisms that contribute to AML pathogenesis. We recently showed
Autor:
Rhese Thompson, Anupriya Agarwal, Jack W. Singer, Ujwal Shinde, Shawn Mahmood, Monika A. Davare, Brian J. Druker, Megan M. Cleary, Johannes Elferich, Steve Kurtz
Publikováno v:
Blood. 126:570-570
Background: A momentous challenge in the treatment of acute myeloid leukemia (AML) is the significant molecular heterogeneity in driving abnormalities and rapid emergence of resistance. Successful clinical translation of novel targeted agents has bee